Related Experiment Video

Updated: May 17, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Par-4 as a potential target for cancer therapy

Rosalyn B Irby1, Christina L B Kline

  • 1Penn State Hershey Cancer Institute, 500 University Drive, Hershey, PA 17033, USA. rirby@hmc.psu.edu

Expert Opinion on Therapeutic Targets
|October 16, 2012
PubMed
Abstract

Insights

The tumor suppressor protein Par-4 (Partner and Localizer 4) selectively induces cancer cell death. Enhancing Par-4 levels or activity shows promise for inhibiting tumor growth in difficult-to-treat cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Cancer remains a leading global cause of mortality, with incidence projected to rise.
  • Novel therapeutic strategies are crucial, especially for challenging cancer types.
  • Par-4, a tumor suppressor protein, selectively induces apoptosis in cancer cells without harming normal cells.

Purpose of the Study:

  • To summarize the mechanisms of Par-4-induced cell death.
  • To discuss the regulation of Par-4 in cancer cells.
  • To review methods for overexpressing or activating Par-4 for therapeutic benefit.

Main Methods:

  • Literature review of studies on Par-4 mechanisms and therapeutic strategies.
  • Analysis of in vitro and in vivo approaches to modulate Par-4.
  • Evaluation of the impact of increased Par-4 levels/activity on cancer cells.

Main Results:

  • Par-4 induces apoptosis through specific cellular mechanisms.
  • Dysregulation of Par-4 is observed in cancer cells.
  • Experimental approaches demonstrate successful enhancement of Par-4 levels/activity.
  • Increased Par-4 leads to enhanced apoptosis susceptibility and inhibited tumor growth.

Conclusions:

  • Par-4 is a potent therapeutic candidate for cancer treatment due to its cancer-selective apoptosis induction.
  • Targeting Par-4 offers a potential advantage over traditional chemotherapeutics by minimizing side effects.
  • Further research is needed to optimize Par-4-based therapies for clinical application.

More Related Videos

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase09:51

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Published on: June 30, 2023

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...